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Membranoproliferative glomerulonephritis
recurrence after kidney transplantation:
using the new classification
Sami Alasfar1, Naima Carter-Monroe2, Avi Z. Rosenberg3, Robert A. Montgomery4 and Nada Alachkar1*

Abstract
Background: Membranoproliferative glomerulonephritis (MPGN) is an uncommon glomerular disorder that may
lead to end stage renal disease (ESRD). With new understanding of the disease pathogenesis, the classical classification
as MPGN types I, II, III has changed. Data on post-transplant MPGN, in particular with the newly refined classification, is
limited. We present our center’s experience of MPGN after kidney transplantation using the new classification.
Methods: This is a retrospective study of 34 patients with ESRD due to MPGN who received 40 kidney
transplants between 1994 and 2014. We reviewed the available biopsies’ data using the new classification.
We assessed post transplantation recurrence rate, risk factors of recurrence, the response to therapy and
allografts’ survival.
Results: Median time of follow up was 5.3 years (range 0.5–14 years). Using the new classification, we found
that pre-transplant MPGN disease was due to immune complex-mediated glomerulonephritis (ICGN) in 89 %
of cases and complement-mediated glomerulonephritis (CGN) in 11 %. Recurrence was detected in 18 transplants
(45 %). Living related allografts (P = 0.045), preemptive transplantations (P = 0.018), low complement level (P = 0.006),
and the presence of monoclonal gammopathy (P = 0.010) were associated with higher recurrence rate in ICGN cases.
Half of the patients with recurrence lost their allografts. The use of ACEi/ARB was associated with a trend toward less
allograft loss.
Conclusions: MPGN recurs at a high rate after kidney transplantation. The risk of MPGN recurrence increases with
preemptive transplantation, living related donation, low complement level, and the presence of monoclonal
gammopathy. Recurrence of MPGN leads to allograft failure in half of the cases.
Keywords: MPGN, Kidney transplant, C3 glomerulopathy, Immune complex GN

Background
Membranoproliferative glomerulonephritis (MPGN) is
an uncommon glomerular injury pattern characterized
by mesangial hypercellularity, endocapillary proliferation,
and capillary-wall remodeling. MPGN accounts for approximately 7 to 10 % of all cases of biopsy-confirmed
glomerulonephritis [1, 2]. The clinical presentation is
variable depending on the pathogenesis involved and the
timing of biopsy, and could range from asymptomatic
hematuria and/or proteinuria to rapidly progressive
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glomerulonephritis [3]. Standardized optimal treatment
of MPGN is not determined. Commonly used therapies
include: glucocorticoids, azathioprine, mycophenolate
mofetil, cyclophosphamide, rituximab, plasmapheresis,
and eculizumab. There are no randomized controlled
trials that assess the effectiveness of individual interventions due in part to the rarity of MPGN. In up to
50 % of the cases, MPGN may take a progressive course
and lead to end stage renal disease (ESRD) within 8–10
years of presentation [4].
Historically, MPGN has been classified into three
types based on the location and the appearance of immune deposits under observed electron microscopy
(EM). MPGN type I is by far the most common form
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and characterized by subendothelial and mesangial deposits. MPGN type II, also known dense deposits disease, is characterized by highly osmiophilic dense
deposits within the lamina densa of the glomerular
basement membrane. MPGN type III is characterized
by subepithelial and subendothelial deposits [5]. Certain
systemic diseases such as chronic hepatitis C, autoimmune diseases, and plasma cell dyscrasias, have been
associated with MPGN and in these cases it is called
secondary MPGN and by histomorphology may present
as MPGN types I or III [6].
Recent advances in understanding the pathophysiology
of MPGN and the role of the alternative complement
pathway have led to the development of a new classification system of MPGN types. This classification is based
on the mechanism involved in the glomerular injury rather than the location of and appearance of deposits.
This may help to direct the clinical evaluation and provide more pathophysiology-specific treatments. It has
been known that the classic glomerular injuries seen in
MPGN are the results of the deposition of immunoglobulins, complement factors, or both in the glomerular
mesangium and along the glomerular capillary walls.
These can be distinguished by immunofluorescence microscopy. Therefore, MPGN can be viewed as either
immune-complex-mediated glomerulonephritis (ICGN)
which is characterized by the presence of immune complexes and complement components, or complementmediated (CGN) which is characterized by the presence
of complement components in the absence of immune
complexes.
Several observational studies assessed MPGN recurrence after kidney transplantation, however, the data on
the natural course of MPGN recurrence, impact on renal
allograft, and its treatment remains limited due to the
low number of patients and short follow-up time in
these studies. In addition, these studies assessed MPGN recurrence based on the old classification system. MPGN
often recurs after kidney transplantation and the reported
rate of recurrence of MPGN is quite variable (19–65 %) depending on the study [7–9]. What was formerly called
MPGN type II was found to be associated with the highest
rate of recurrence after transplantation [10, 11]. Recurrence
after transplantation was found to be associated with the
presence of monoclonal immunoglobulins [8], lower serum
complement level [8], higher proteinuria [11], human
leukocyte antigen (HLA) B8, DR3 [9], B49, and DR4 [7],
and the presence of crescents in the original biopsy [11].
We, herein, share our center’s experience of kidney
transplantation course in patients with ESRD due to
MPGN. We assessed several possible risk factors as well
as recurrence rate, the impact of the recurrence on
renal allografts, and the response to treatment; all in
light of the new MPGN classification.
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Methods
Study design

This is a 20-year retrospective study of all patients with
MPGN who received kidney transplantation in our
center. The study was approved by the Johns Hopkins
Medicine Institutional Review Board. We identified 34
patients with ESRD due to MPGN who received 40
total kidney transplantations in our institution between
January 1994 and September 2014. We confirmed the
diagnosis by reviewing all the available biopsy data in
the patients’ medical records, in addition to a second
review of the biopsies by our pathologist for the purpose of this study. The other purpose of the second
review of all the biopsies was to utilize the new classification of the MPGN types. We aimed to assess the
clinical outcome of the patients and allografts using
the new classification of MPGN. We also identified
the risk factors of recurrence, response to therapy
and long-term prognosis. After we confirmed the
diagnosis of MPGN of our cohort, we reviewed all
available medical records and we collected the pertinent clinical data.

Clinical data

Five patients had repeated transplants. One patient had
3 transplants; the first failed due to vascular thrombosis,
the second failed due to MPGN recurrence and rejection, and the third failed due to severe acute tubular
injury (ATN). The second patient had 2 transplants;
the first failed due to ATN, and the second did not fail
but it had MPGN recurrence. The third patient had 2
transplants and both failed due to MPGN recurrence.
The fourth patient had 2 transplants, the first failed
due to rejection (with no recurrence) and the second
did not fail and had no recurrence. The fifth patient
had 2 transplants; both failed due to rejection and
MPGN recurrence.

Statistical analysis

We performed our statistical analyses using STATA 13
statistical software (StataCorp LP, College Station, Texas,
USA). Descriptive statistics were used to estimate the
frequencies, means, medians, and proportions of the
study variables. We checked normality of distribution
for continuous variables using box plots, normal probability plots, and Shapiro/Wilk normality test. Continuous
data were expressed as median and range or mean and
standard deviation. We used survival analysis/KaplanMeier curve to present all allograft survivals. We used
Cox regression models to compare between the recurrence and non-recurrence groups. A P-value of <0.05 is
considered statistically significant.
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Results
Patients’ characteristics are shown in Table 1. Mean age
at transplantation was 37.4 ± 13.5 years. Half of the
transplants were done in men. Twenty-eight (70 %) out
of the allografts were done in Caucasians and seven
(17 %) were done in African-American. Out of these 40
transplantations, 4 (10 %) were preemptive. Livingrelated donors kidney transplants were performed in 15
of all transplants, additional 15 were from living unrelated donors, and the remainders were from deceased
donors. All cases were biopsy confirmed MPGN; 65 %
were diagnosed as MPGN type I, 9 % were MPGN type
II, 21 % were MPGN type III, and 5 % had features of
both MPGN type II and III. Upon reclassification using
the new classification system, 88 % were ICGN and
12 % were CGN. None of the cases were dense deposits
disease.
Most of the cases were classified as idiopathic MPGN.
In regards to secondary causes of MPGN, hepatitis C
(HCV) antibodies and positive serum HCV PCR were
Table 1 Transplants’ Characteristics
Variable

Transplants (n = 40)

Median age at transplantation- yr (range)

37.4 (15–59)

Gender (Male)

20 (50 %)

Race: Caucasian

28 (70 %)

African American

7 (17 %)

Other

5 (13 %)
a

MPGN type (Old classification ): Type I

65 %

Type II

9%

Type III

21 %

Mixed

5%
b

MPGN type (New classification ): ICGN
CGN
Donor source: Deceased

88 %
12 %

positive in only one transplant. Fifteen of the total 40
transplants had cryoglobulin checked and it was negative
in all of them. None of the patients had evidence of
other autoimmune disease such as positive ANA, anti
dsDNA, rheumatoid factor, or anti SSA/SSB antibodies.
None had a diagnosis of malignancy prior to transplant.
In regards to monoclonal gammopathy and/or myeloma
as a cause of MPGN, we identified 19 patients who had
serum and/or urine electrophoresis checked and only 7
of them had evidence of a monoclonal spike. None of
the patients had a diagnosis of frank multiple myeloma
prior to transplant but one patient, who also had a
monoclonal spike prior to transplant, developed multiple
myeloma after transplant. Based on the data we have we
could not tell whether some of the cases were secondary
to a systemic infection. Cumulative mean ESRD duration
prior to transplant in non-preemptive transplants was
5.2 (0.25–20) years. Only 2 out of the 40 transplants
were ABO incompatible. Induction immunosuppression
was thymoglobulin in 23, daclizumab in 15, and basiliximab in 2 of the transplantations. All cases, except
one, received calcineurin inhibitor- based maintenance
immunosuppression; one received mammalian target
of rapamycine (mTOR inhibitor)- based therapy. Five
out of the 40 transplants had delayed graft function
(DGF) after transplantation. Seven cases were placed
on angiotensin-converting enzyme (ACE) inhibitors or
angiotensin receptor blockers (ARB) after kidney
transplantation. Median duration of follow up period is
5.3 years (range 0.5–14 years). Two patients died during the follow up period following graft loss and the
cause of death is not available to us. Seventeen of the
forty renal allografts (42 %) failed due to different reasons other than MPGN recurrence. Causes of graft loss
are shown in Table 2.

10 (25 %)

MPGN recurrence

Living unrelated

15 (37 %)

Living related

15 (37 %)

Post-transplant recurrent MPGN was detected in 18
out of the 40 transplants (45 %). When clinically indicated, diagnosis was made by renal allograft biopsies.
Indications for obtaining renal allograft biopsy in these

Number of mismatches
0

1 (2 %)

1

3 (7 %)

2

5 (12 %)

Reason for graft loss

Frequency

3

10 (25 %)

MPGN recurrence

6

4

7 (17 %)

Antibody-Medicated Rejection

2

5

7 (17 %)

Cell-Medicated rejection

2

6

6 (15 %)

MPGN recurrence & rejectiona

3

Preemptive kidney transplant

4 (10 %)

ATN

2

Median cumulative ESRD duration
for non-preemptive- yr (range)

5.2 (0.2–20)

Bleeding

1

Thrombosis

1

a

Old classification is based on location and appearance of immune deposits
under electron microscopy
b
New classification is based on C3 and IgG staining with immunofluorescence

Table 2 Reasons for renal allografts loss

a

In the three cases recurrence preceded rejection and the rejection was
antibody mediated
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develop post-transplant recurrent MPGN and had
complement levels available had normal C3 and C4
levels. This difference was statistically significant
(P = 0.006) with a hazard ratio (HR) of 5.5.
2) Monoclonal gammopathy:
To assess the frequency and association of plasma
cell dyscrasias and MPGN recurrence, we identified
a total of 19 patients who had serum or urine
protein electrophoresis checked at some point
before or after kidney transplantation. Out of the
ICGN cases, 6ix of the 10 (60 %) patients, who
developed post-transplant recurrent MPGN and had
serum or urine electrophoresis available, had
monoclonal proteins. On the other hand, only 1 out
of the 9 (11 %) patients, who did not develop
post-transplant recurrent MPGN and had serum or
urine electrophoresis available, had monoclonal
protein. This difference was also statistically
significant (P = 0.01) and with a HR of 5.6.
3) Allograft type
Among the ICGN cases, when the source of donor
was evaluated, living-related kidney transplants were
associated with the highest risk of recurrence 8 out
of 13 (61 %) compared to the other types (livingunrelated and deceased donor) 87 out of 20 (35 %),
P = 0.045 and HR of 10.41.

patients included: decreased estimated glomerular filtration rate (eGFR) (10 allografts), proteinuria (4 allografts), decreased eGFR and proteinuria (3 allografts),
and protocol post-transplant biopsy (1 allografts). Ten
out of the 18 (55 %) recurrences were diagnosed within
the first year post-transplant. Median time to recurrence was 8 months (range 1–108 months). Table 3
shows the characteristics of patients who developed
post-transplant MPGN recurrence.
Factors associated with MPGN recurrence

Table 4 shows the effect of different variables associated
with MPGN recurrence after kidney transplantation by
univariate Cox analysis. We only included ICGN patients in analysis because of the small number of CGN
patients and the difference in pathophysiology involved.
1) Complement:
Levels of the serum complement component C3
and/or serum complement component C4 were
available in 22 out of the 40 transplants (56 %) in
pre-transplant period. Among the ICGN cases, eight
of the thirteen (72 %) patients who developed posttransplant recurrent MPGN and had complement
levels available, had either low C3 or C4 level. On
the other hand, all (100 %) 9 patients who did not

Table 3 Shows characteristics of allografts with post-transplant MPGN recurrence
Graft

MPGN type (Native/Rec)

Age at
Txp

Sex/Race

Donor

Months to
recurrence

sCr

Proteinuria(g)

Rx

Graft status/
sCr

IC/IC

20

F/AA

LR

2

1.4

4

None

Functional/1.6

1 /1

IC/IC

39

F/C

LR

3

1.2

9

CS + ACEi

Functional/ 2.5

1 a/1

C3/IC

59

F/C

LR

1

0.9

2.7

None

Functional/0.9

LR

24

2

2.3

Ritux + CS

Lost in 22 mos

D

24

3

NA

CS

Lost in 96 mos

LU

36

2.5

4

TPE + CS

Lost in 4 mos

LR

18

NA

NA

None

Lost in 1 mos

M/A

LR

6

1.8

0.1

Ritux

Functional/1.2

M/AA

D

4

1.0

2

ACEi

Functional/1.0

By EM

By IF

1

1/1

2

a

3
4

1/1

IC/IC

26

M/C

5

2 + 3/2 + 3

IC/IC

53

M/C

6

a

3 /1

IC/IC

18

M/I

7

3 a/?

IC/IC

15

M/I

8

1/1

IC/IC

28

9

1/1

IC/IC

54

10

1/1

IC/IC

53

M/C

D

4

1.7

0.5

TPE+ ACEi

Functional/1.2

11

3a/1

IC/IC

30

F/C

LR

108

2.0

0.45

Ritux

Functional/2.5

12

2/2

IC/IC

54

M/C

LU

24

3.4

NA

Ritux

Lost in 2 mos

13

1/1

IC/IC

51

F/C

LU

1

1.9

0.8

TPE + Ritux

Functional/1.7b

14

1a/1

IC/IC

32

M/H

LR

24

1.7

4

TPE + Ritux

Lost in 41 mos

15

1/1

IC/IC

25

F/C

LR

14

1.3

9.5

Ritux

Lost in 4 mos

16

1/1

IC/IC

53

F/AA

LR

12

NA

NA

CS

Lost in 8 mos

17

1/2

IC/C3

58

F/AA

D

6

3.1

NA

None

Lost in 5 mos

18

1/1

C3/C3

24

M/C

LU

3

1.3

0.2

Eculizumab

Functional/1.3

Txp transplant, IC immune complex, sCr serum Creatinine, Rx Treatment, AA African American, C Caucasian, I Indian, A Asian, H Hispanic, LR living related, LU living
unrelated, D: deceased, CS corticosteroids, ACEi Angiotensin Converting Enzyme inhibitor, TPE therapeutic plasma exchange, Ritux Rituximab, NA not available
a
MPGN type by documentation but kidney biopsy slides are not available for review. All others are classified based on kidney biopsy slides review
b
Patient diagnosed with plasma cell dyscrasia and received chemotherapy
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Table 4 Variables associated with MPGN ICGN-type recurrence
after kidney transplantation by univariate Cox analysis (allograft
n = 35)
Independent variable

Hazard ratio (CI)

P-value

Age at transplantation

1.019 (0.937–1.018)

0.65

Gender (Male)

1.00 (0.118–8.420)

1

Race (Caucasian)

1.5 (0.120–18.411)

0.1

Allograft source (Living related)

10.19 (0.866–12.96)

0.045

Duration of dialysis

0.951 (0.775–1.167)

0.612

Preemptive transplantation

6.322 (1.455–12.411)

0.018

Previous failed transplantation

0.833 (0.098–7.026)

0.86

DGF (In deceased donor)

1.21 (0.158–9.508)

0.83

Development of rejection

3.148 (0.854–9.546)

0.25

Use of ACEi/ARB

1.312 (0.587–5.847)

0.658

Low complement level

5.522 (1.632–18.679)

0.006

Evidence of monoclonal gammopathy

5.606 (1.522–20.642)

0.010

Only cases with confirmed MPGN type by kidney biopsy review and/or
nephrology documentation are included

4) Type of MPGN:
Based on the historical (EM based) classification of
MPGN, none of the specific MPGN subtypes were
associated with a higher risk of recurrence
compared to the other types (HR of 1.901 and
P = 0.28). After reclassification the original MPGN

based on immunofluorescence pattern, we did not
observe any association between MPGN class and
recurrence after transplantation (HR 0.6 if ICGN
and P = 0.50).
5) Other factors:
There was no effect for race, gender, age, number of
transplants, degree of mismatch, and development of
DGF or rejection on risk of recurrence. Duration of
dialysis prior to transplant was not associated with increased risk of MPGN recurrence. However, preemptive
transplant was associated with increased risk of posttransplant recurrent MPGN (HR of 6.32 and P = 0.018).

MPGN recurrence reclassification

We reviewed allograft biopsies that showed post-transplant
MPGN recurrence and reclassified the 18 recurrences
using the new MPGN classification system (Fig. 1). Table 5
delineates the MPGN subtypes of all post-transplant recurrences. In one of the recurrences reclassified as an ICGN,
the type of MPGN changed in subsequent biopsies to
CGN. Notably, this switch was observed following treatment with plasmapheresis. Additionally, there was a case
of ICGN type that recurred with IgA dominance, in contrast to the original disease, which was a classic ICGN with
IgG dominance. More interestingly, there was a case whose

Fig. 1 Histological changes of MPGN in kidney transplant biopsies. Typical light microscopic (LM), electron microscopy (EM) and immunofluorescence
(IF) finding in cases previously classified as MPGN. Panel on left demonstrates a case reclassified as ICGN with C3 abnormalities, including (a) the classic
MPGN pattern glomerulonephritis on LM (hematoxylin and eosin ×400), (b) large subendothelial electron dense deposits on EM (×1250 K) and granular
mesangial and capillary wall staining for both (c) IgG and (d) C3 on IF. The panel on the right shows a case reclassified as a C3 glomerulopathy, with (e) a
similar MPGN pattern on light microscopy (hematoxylin and eosin ×400), (f) smaller subendothelial deposits on EM (×7100) and granular mesangial and
capillary wall staining for (g) C3, but no significant staining for (h) IgG. EM images stained with lead citrate/ uranyl acetate. Immunofluorescence stains are
FITC-conjugated goat anti-human IgG (MP Biomedical) and FITC-conjugated goat anti-human C3 (Kent) all at × 400
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Table 5 Reclassified based on immunofluorescence C3 and IgG
findings

Table 7 Response of post-transplant MPGN recurrence to
different treatments

Recurrence type at time
of diagnosis (new classification)

Treatment

Number of cases

Recurrence type at
time of diagnosis
(old classification)

ICGN

15

Type I: 14, Type III:1

CGN

2

Type I: 1, Type II: 1

ICGN-IgA dominant

1

Type I

ICGN immune complex mediated glomerulonephritis, CGN Complement
mediated glomerulonephritis

Number of allografts

Response to therapya

High dose steroids

4

1

Rituximab ±
plasmapheresis

8

3

Plasmapheresis

1

1

Eculizumab

1b

1

No change in therapy

4

3

a

original disease was CGN but the recurrence fits the criteria of an ICGN diagnosis.
Treatment and outcome of post-transplant recurrent
MPGN

Fourteen allografts out of the 18 recurrences received
MPGN specific immunosuppressive therapy (Tables 6 & 7).
Among the ICGN recurrences, immunosuppressive therapy
included high-dose corticosteroids in 4 allografts, Rituximab in 5 allografts, plasma exchange alone in one allograft,
plasma exchange with rituximab in 3 allografts. There are 2
cases of recurrence of CGN type and one of them was
treated with eculizumab. One ICGN recurrence case was
also found to have multiple myeloma and was treated with
bortezomib. In 7 out of the 16 (43 %) transplants who developed post-transplant MPGN recurrence of ICGN type,
the recurrence led to graft loss. In one of the two transplants who developed post-transplant MPGN recurrence of
CGN type, the recurrence led to graft loss. The median
time to graft loss after diagnosis in patients who lost their
renal allografts was 6.5 months (range 2–18 months). Survival analysis among ICGN cases showed that overall renal
Table 6 Variables associated with allograft loss among patients
with MPGN ICGN-type recurrence after kidney transplantation
by univariate Cox analysis (n = 16)
P-value

Independent variable

Hazard ratio (CI)

Age at transplantation

0.658 (0.326–1.815)

0.471

Gender (Male)

3.541 (0.325–11.785)

0.478

Race (Caucasian)

1.547 (0.354–7.548)

0.785

Allograft source (Living related)

1.547 (0.302–7.548)

0.914

Duration of dialysis

0.894 (0.541–1.325)

0.345

Preemptive transplantation

1.547 (0.458–5.879)

0.995

Previous failed transplantation

2.54 (00.485–9.356)

0.452

DGF (In deceased donor)

2.483 (0.4321–13.578)

0.546

Development of rejection

0.245 (0.008–3.024)

0.454

Use of ACEi/ARB

0.452 (0.081–0.952)

0.06

Low complement level at recurrence

4.201 (1.919–17.679)

0.022

Evidence of monoclonal gammopathy

3.054 (1.125–117.896)

0.45

DGF delayed graft function. ACEi/ARB angiotensin converting enzyme inhibitor/
receptor/angiotensin receptor blocker

Response to therapy defined by improvement in GFR and no subsequent graft loss
b
The case was CGN

allograft survival was not statistically different in both recurrent and non-recurrent groups although there was a
trend of worse survival in the recurrent group (P log rank
of 0.051) (Fig. 2).
Among cases of post-transplant MPGN recurrence,
there was no statistically significant effect for age at
transplantation, gender, race, allograft source, degree of
mismatch, preemptive transplantation, severity of proteinuria at recurrence, development of rejection, complement level, or time to recurrence on graft loss
(Table 6). However, the use of ACEi/ARB therapy was
associated with a trend towards less graft loss (HR 0.301
and P = 0.07) that did not reach a statistical significance.

Discussion
This study presents one of the largest case series of
post-transplant MPGN recurrence in the literature and
the first study to use the new MPGN classification system in assessing post-transplant MPGN recurrence. In
this study, we demonstrated that post-transplant MPGN
recurrence is quite common. We report a recurrence
rate of 45 %. However, we do not routinely perform
protocol post-transplant biopsies in our center and these
data may underestimate the actual recurrence rate. In
the study by Lorenz et al., the reported recurrence rate
among MPGN type I patients is 41 % [8]. Moroni et al.
reported a recurrence rate of 25 % among MPGN type I
patients [12]. Green et al. reported a recurrence rate of
only 19 %, and Braun et al. reported a recurrence rate
among pediatric MPGN type II patients of 43 % [7, 11].
Thus the recurrence rate that we report is generally consistent with that reported in previous cohorts.
Consistent with previous reports, 55 % of MPGN recurrences were diagnosed within the first year of kidney
transplantation. In the studies by Lorenz et al. and
Green et al., all cases were diagnosed within 1.2 and
2.6 years of transplantation respectively [7, 8].
In our cohort, MPGN recurrence led to graft loss in
half of the cases. This is consistent with the study by
Moroni et al. in which graft loss occurred in 56 % of patients [12]. However, other studies showed different outcomes. In the study by Green et al., the recurrence led
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Fig. 2 Kaplan Meier of allografts’ survival in patients with MPGN of ICGN type as original disease

to graft loss in 88 %, as opposed to the observations by
Lorenz et al., in which 16 % lost their grafts.
Our study analysis identified several factors associated
with post-transplant MPGN recurrence. Lorenz et al.
noted that living related transplantation may be associated with higher risk of recurrence but this did not reach
statistical significance (P = 0.051) [8]. This observation
was noted in the study by Green et al. as well, but this
finding did not reach statistical significance either [7].
Our study demonstrated that living related donation is
actually associated with higher risk of recurrence and
this was statistically significant. This interesting association may be attributed to the possible common genetic
predisposition in relatives of MPGN patients.
Interestingly, all preemptive transplants in our study
developed MPGN recurrences, a significant difference
with the balance of the cohort. This finding could be
explained by the presence of continued underlying immune activity that would probably become suppressed
by the immunosuppressive state of dialysis. However, we
did not find an association between the duration of
dialysis prior to transplantation and the development of
recurrence. This contrasts with the findings of Green et
al., wherein a trend toward association between shorter
duration of dialysis before transplantation and recurrence
was observed [7]. However, it is important to point out
that our study remains a retrospective and a small study
after all and we cannot ascertain these associations or
prove causality.
In addition, our investigation confirmed the previous
findings that low complement levels and the presence of
monoclonal gammopathy are associated with higher risk

of recurrence in ICGN cases [8, 12]. The association of recurrence with the presence of monoclonal gammopathy
suggests that it may play a role in the pathogenesis of
MPGN. One of our study patients who developed recurrence and had evidence of monoclonal gammopathy was
later diagnosed with multiple myeloma and received bortezomib and rituximab. This patient maintained an excellent allograft outcome following treatment. The remainder
of patients who had a recurrence of MPGN and evidence
of MGUS in their serum and/or urine did not develop
myeloma afterwards during the time of follow up.
In this series, patients who developed recurrence
did not have worse allografts survival than those who
did not, although graft loss after recurrence was high.
It is pivotal to point out that the failure to demonstrate a difference in the outcome could be related to
the small sample size. Furthermore, our study illustrates that clinically significant post-transplant MPGN
recurrence responds poorly to immunosuppressive
therapy. Less than half of the patients who received
treatment in the form of high dose steroids, rituximab
and/or plasmapheresis, or eculizumab responded to
therapy and maintained their renal allografts. Interestingly, our study demonstrates the possible benefit of
ACEi or ARB therapy in preventing graft loss. However,
this should be interpreted carefully as patients who
received such therapy are those who had stable renal
function.
With regards to MPGN reclassification, most of the
native and recurrent MPGN cases were reclassified to
ICGN. This was expected because overall CGN is less
common than ICGN. However, we observed a few cases

Alasfar et al. BMC Nephrology (2016) 17:7

in which the MPGN class changed over time. One patient whose original disease was CGN (confirmed by two
biopsies) developed a recurrence after two years of
transplantation that was reclassified as ICGN based on
two separate biopsies several months apart. Another patient whose original disease was an ICGN (also confirmed by two biopsies) developed a recurrence of the
CGN type. In these cases, it is difficult to distinguish
whether this is a change in disease pattern or a development of de novo MPGN of different subtype. Based on
the old classification, pre- and post- transplant biopsies
were labeled as MPGN type I in both of the cases. More
interestingly, there was one case with ICGN original disease that developed an MPGN recurrence. The first biopsy that showed recurrence was reclassified as ICGN
but a subsequent biopsy five months later was reclassified to CGN. The change of type was noted after treatment with plasmapheresis. These findings shed the
light on the possible change in microscopic findings of
MPGN over time. This might be a problematic when
deciding to treat this condition since the choice of
treatment is dependent on the MPGN type.
There are some limitations to our study. It is a retrospective cohort study; hence there could be information
bias due to missing data and we cannot prove causality
in our findings. Although this is one of the largest studies
that assessed post-transplant MPGN recurrence, it is a
rare disease and the number of patients available for the
study is small. Also, because the majority of our study
population was type I and reclassified to ICGN, our study
was not powered to detect differences in recurrence and
outcome between the different types of MPGN. In other
studies, the risk of recurrence in CGN was reported to be
as high as 67 % [13].

Conclusions
The positive findings of our study highlight several issues regarding kidney transplantation in ESRD patients
due to MPGN. If these findings are confirmed by future
prospective studies, extra effort should be made to look
for living non-related donors. In the case of living related donors, a close surveillance is required after transplanting patients from living related donors. The same
applies in the case of preemptive transplantation. These
patients, along with patients with low complement level,
should be intensively monitored for signs of disease recurrence or the transplant should be deferred to a time
when recurrence is less likely. Our study confirmed the
previously noted association of monoclonal gammopathy
with MPGN recurrence. This finding should alert the
transplant teams to perform screening for monoclonal
gammopathy in MPGN patients undergoing evaluation
for kidney transplantation. A referral to hematology may
be required and close monitoring after transplantation
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should be employed in these cases. We should counsel
MPGN patients undergoing kidney transplantation that
this disease commonly recurs, and in many cases recurrence leads to graft loss. We should also be alert for the
possibility of change of pathological findings of MPGN
over time, which may alter our decision on treatment,
and more frequent follow up biopsies may be warranted.
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